Introduction {#s1}
============

Neuregulin 1 (*Nrg1*) is a neurotrophic factor that mediates its effects by binding ErbB receptor tyrosine kinases. *Nrg1* regulates axonal guidance, myelination, and GABAergic and glutamatergic neurotransmission (Mei and Xiong, [@B59]). The human *NRG1* gene has been linked to schizophrenia by genetic studies (Stefansson et al., [@B85]; Ayalew et al., [@B5]) and altered expression of *NRG1* isoforms has been measured in schizophrenia patients (Hashimoto et al., [@B35]; Chong et al., [@B21]; Marballi et al., [@B55]; Weickert et al., [@B96]). *NRG1* variants have been associated with dysfunction in a number of schizophrenia-relevant "endophenotypes" including sensorimotor gating as measured by prepulse inhibition of startle (PPI) (Hong et al., [@B40]; Roussos et al., [@B74]; Greenwood et al., [@B33]) and working memory (Chong et al., [@B21]).

Use of transgenic murine models can be useful in exploring the role of *Nrg1* in molecular neurobiology and behavior. The most extensively studied mouse model of *Nrg1* dysfunction is the *Nrg1* transmembrane heterozygous (*Nrg1* HET) mouse which exhibits locomotor hyperactivity and protocol-dependent PPI deficits (Stefansson et al., [@B85]; Karl et al., [@B44]; Spencer et al., [@B84]). These mice display altered anxiety profiles, inhibited preference for social novelty and increased levels of aggressive social interaction as well as impaired performance in novel object recognition and fear conditioning paradigms (Karl et al., [@B44]; O\'Tuathaigh et al., [@B66], [@B67]; Duffy et al., [@B26]; Desbonnet et al., [@B25]). Hypo-phosphorylation of the NR2B subunit of the NMDA receptor is observed in *Nrg1* HET mice (Bjarnadottir et al., [@B9]). Together, these findings provide some clues of the molecular and neurobiological alterations that mediate the aberrant behavioral phenotypes exhibited by *Nrg1* HET mice.

Adolescence is particularly relevant to schizophrenia given the onset of the disorder typically occurs in late adolescence. During adolescence there exists significant synaptic pruning and a shift between utilization of mesolimbic and mesocortical areas of the brain which indicates a high level of neural development during this period (Giedd et al., [@B32]; Spear, [@B83]; Casey et al., [@B16]). *Nrg1* HET mice display developmentally-specific neurobiological and behavioral phenotypes, for example, adolescent *Nrg1* HET mice have reduced 5-HT~2A~ receptor expression in the insular and cingulate cortices (Long et al., [@B54]) in contrast to the global increase in 5HT~2A~ receptor expression observed in adult *Nrg1* HET mice relative to controls (Dean et al., [@B24]). *Nrg1* HET mice display an enhanced stress-induced release of corticosterone relative to wildtype (WT) controls at 3--4 months of age, an effect that disappears by 5--6 months (Chesworth et al., [@B20]). Together these findings point toward the *Nrg1* HET mouse being a particularly suitable model for demonstrating a role for *Nrg1* in developmental stage-specific neurobehavioral alterations.

Drug dependence and schizophrenia are comorbid disorders that may have common genetic and neurobiological substrates. Genetic vulnerability is thought to explain why only a subset of cannabis users become dependent on cannabis or develop psychosis. A recent study demonstrated that *NRG1* increased the risk of cannabis dependence in African-Americans (Han et al., [@B34]). We have shown *Nrg1* HET mice display distinct schizophrenia-relevant neurobehavioral responses to cannabinoids, including the main psychoactive constituent of cannabis, Δ^9^-tetrahydrocannabinol (THC). Acute cannabinoid exposure promoted PPI facilitation in *Nrg1* HET mice but PPI deficits in WT mice (Boucher et al., [@B10], [@B12]). *Nrg1* genotype also modulated tolerance to the effects of cannabinoids, with *Nrg1* HET mice developing tolerance more rapidly to locomotor suppression and hypothermia than WT mice, but conversely showing a lack of tolerance to cannabinoid-induced anxiety unlike WT mice (Boucher et al., [@B12]). The acute and repeated effects of cannabinoids correlate with selective changes in Fos transcription factor expression in the lateral septum of *Nrg1* HET mice that were not observed in WT mice (Boucher et al., [@B11], [@B12]). In adolescence *Nrg1* modulated the effects of repeated THC exposure on the expression of neurotransmitter receptors relevant to the pathophysiology of schizophrenia (i.e., CB~1~, NMDA, and 5-HT~2A~ receptors) (Long et al., [@B54]).

The hippocampus may be an important region for *Nrg1*-cannabinoid interactions as both endocannabinoid and *Nrg1*-ErbB systems are highly expressed in this brain region (Herkenham et al., [@B37]; Tsou et al., [@B90]; Vullhorst et al., [@B93]). We have observed increased brain transcriptional activity in the lateral septum at baseline and following cannabinoid exposure in *Nrg1* HET mice, both of which might reflect downstream effects of aberrant activity in the hippocampus as part of the septohippocampal system. Therefore, molecular changes in the hippocampus may subserve the distinct neurobehavioral phenotypes displayed by *Nrg1* HET mice as well as their altered response to THC. Of particular interest is our observation that adolescent THC--treated *Nrg1* HET mice display increased NMDA receptor expression in the hippocampus, something not observed in THC-treated WT mice (Long et al., [@B54]). Here we aim to gain some traction on the molecular mechanisms involved in the aberrant phenotypes exhibited by *Nrg1* HET mice at baseline and when exposed to THC using a proteomic approach which allows us to detect changes in hundreds of different proteins in the hippocampus.

Materials and methods {#s2}
=====================

Animals and drug treatment
--------------------------

At the commencement of the study adolescent male *Nrg1* HET mice and WT littermates (C57/BL6 background strain) were at an age of post-natal day (PND) 31 ± 2. The study was restricted to male mice as male *Nrg1* HET mice appear more vulnerable to the effects of cannabinoids (Long et al., [@B53]). Mice were pair-housed at Neuroscience Research Australia with limited environmental enrichment \[certified polycarbonate mouse igloo (Bioserv, USA) and a metal ring in the cage lid\] under a 12 h light/dark schedule (lights on 08:30 h) and genotyped as previously detailed (Karl et al., [@B44]). Food and water were available *ad libitum*. THC (THC Pharm GmbH, Germany) was suspended in a 1:1:18 mixture of ethanol:Tween 80:0.9% saline and injected intraperitoneally at a volume of 10 ml/kg. Mice were injected daily with either 10 mg/kg of THC or vehicle for 21 days. During this time mice were repeatedly behaviorally tested, the results of which are published elsewhere (Long et al., [@B54]). Two days following the completion of treatment, the mice (*n* = 8) were euthanized by cervical dislocation, with both hippocampi dissected out and snap frozen on dry ice for proteomic analysis. Research and animal care procedures were approved by the University of New South Wales Animal Care and Ethics Committee and were in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.

Protein extraction
------------------

Protein extraction was performed using a protocol optimized for cytosolic proteins (Quinn et al., [@B69]). Hippocampal tissue was homogenized in buffer consisting of 7 M urea, 2 M thiourea, 1% C7bZO and 40 mM Tris, sonicated and pelleted. The supernatant was reduced and alkylated in 5 mM tributylphosphine (TBP) and 10 mM acrylamide monomer and quenched using 10 mM dithiothreitol (DTT). The mixture was acidified to pH 6.0 using concentrated citric acid and precipitated with acetone. The precipitate was pelleted, air-dried and resuspended in 7 M urea, 2 M thiourea and 1% C7bZO.

2D gel electrophoresis
----------------------

Sample protein concentration was determined using the Bradford Protein Assay (Thermoscientific, USA). Immobilized pH gradient strips (IPG strips; 11 cm, pH 4--7) were rehydrated with samples containing 600 μg protein, and samples were separated by isoelectric point (pI). Strips were equilibrated in SDS equilibration buffer and loaded onto SDS-PAGE gradient gels (8--16%, 10 × 15 cm) and separated by molecular weight using an ElectrophoretIQ3 system (30 mA/gel, 25°C for 110 min; Proteome Systems, Australia). Gels were fixed with methanol \[25% (v/v)\] and acetic acid \[10% (v/v)\] and visualized using Flamingo Fluorescent gel stain (BioRad, USA).

Image analysis
--------------

Gels were analyzed using Phoretix 2D Expression software (Non-linear Dynamics Ltd, UK). Averaged gels were created for each experimental group and averaging parameters were set at 70%. Single factor ANOVAs (*p* \< 0.05) of spot volume were performed to determine the effect of genotype in vehicle-treated animals, the effect of THC administration in WT mice and the effect of THC administration in *Nrg1* HET mice.

Mass spectrometry and protein identification
--------------------------------------------

Protein spots that were identified as significantly altered were digested in 12.5 ng/mL trypsin (Roche, USA) and 25 nM NH~4~HCO~3~/0.1% trifluroacetic acid and purified using C~18~ purification tips (Eppendorf, Germany) before being eluted in 3 μL of matrix solution. Spots were analyzed using an Applied Biosystems QSTAR MALDI-TOF mass spectrometer (Australian Proteome Analysis Facility, University of Sydney). MALDI spectra were matched against the Swiss-Prot database using the MASCOT search engine with matches determined by molecular weight search score (MWS) and sequence coverage in conjunction with pI and molecular weight as estimated from gels.

Immunoblotting
--------------

Ten ug of protein per lane was separated by electrophoresis using 10% precast NuPage gels (Invitrogen, USA) and run at 110 V for 2 h. The samples were transferred to PVDF membranes. Membranes were sequentially incubated with Syntaxin-1A antibody (Sigma Aldrich, USA 1:1500) then swine anti-rabbit secondary antibody (DAKO, Australia, 1:200) and rabbit Peroxidase-Anti-Peroxidase (Sigma-Aldrich, USA 1:200) and DAB (DAKO, Australia). Membranes were stripped using Re-blot plus strong antibody stripping solution (Millipore, Australia) and incubated sequentially with Abcam rat monoclonal YL1/2 α-tubulin (TUBA) antibody (Sapphire Biosciences Pty Ltd, Australia, 1:) then anti-rat IgG (HþL) horseradish peroxidase conjugate (Santa Cruz Biotechnology Inc, USA) and visualized using a Syngene G:Box.

Results {#s3}
=======

Here we present the results of a hippocampal proteomic study conducted on adolescent *Nrg1* HET mice and WT control mice treated with or without THC. The averaged gels for WT vehicle, WT THC, *Nrg1* HET vehicle and *Nrg1* HET THC contained 870, 821, 761, and 742 spots respectively. 26 spots were significantly different between WT vehicle and *Nrg1* HET vehicle mice. Of these spots, 17 proteins were identified using MALDI-TOF MS and the fold changes from control WT mice are listed in Table [1](#T1){ref-type="table"}. Figure [1A](#F1){ref-type="fig"} shows a representative 2D gel image of protein expression in the hippocampus of a WT mouse administered vehicle. Normalized spot volumes are depicted for three representative proteins are shown in Figure [1B](#F1){ref-type="fig"}, i.e., syntaxin 1A (STX1A), beta-soluble N-ethylmaleimide-sensitive factor attachment protein (β-SNAP) and glypican 6 (GPC6). Western blotting results confirmed *Nrg1* HET mice displayed increased expression of STX1A compared to WT mice (see Figure [1B](#F1){ref-type="fig"}).

###### 

**Adolescent hippocampal proteomics comparing adolescent vehicle-treated WT and *Nrg1* HET mice**.

  **Spot number**                      **Protein name**                                                            **Abbreviation**   **UniProt accession number**   **PI**   **Mass (Da)**   **MWS**   **No. of peptides matched**   **% seq cover**   **Fold change**   ***T*-test (p)**
  ------------------------------------ --------------------------------------------------------------------------- ------------------ ------------------------------ -------- --------------- --------- ----------------------------- ----------------- ----------------- ------------------
  **VESICLE FUNCTION PROTEINS**                                                                                                                                                                                                                                           
  11755                                Syntaxin-1A                                                                 STX1A              O35526                         5.14     33,054          63        5                             20                2.996             0.00123
  11358                                Beta-soluble NSF attachment protein                                         β-SNAP             P28663                         5.32     33,557          80        5                             33                −8.897            0.02521
  11673                                Syntaxin-7                                                                  STX7               O70439                         5.6      29,821          55        4                             22                2.118             0.00333
  11737                                Dynactin subunit 2                                                          DCTN2              Q99KJ8                         5.14     44,117          94        8                             21                2.96              0.03845
  11800                                ADP-ribosyl cyclase 2                                                       BST-1              Q64277                         5.49     34,616          85        5                             37                −1.516            0.04099
  **SEROTONERGIC NEUROTRANSMISSION**                                                                                                                                                                                                                                      
  11967                                Tryptophan 5-hydroxylase 1                                                  TPH1               P17532                         6.06     51,343          82        7                             17                −3.353            0.04087
  11670                                Serotonin N-acetyltransferase                                               AA-NAT             O88816                         7.01     23,069          56        3                             26                1.549             0.00076
  **GROWTH FACTORS**                                                                                                                                                                                                                                                      
  11646                                Secreted protein acidic and rich in cysteine                                SPARC              P07214                         4.77     34,450          71        5                             16                1.388             0.04557
  11294                                Glypican 6                                                                  GPC6               Q9R087                         5.32     63,057          86        7                             20                2.515             0.01623
  11419                                Fibroblast growth factor 14                                                 FGF14              P70379                         10.11    27,764          74        5                             29                −1.61             0.02358
  **CELL SURVIVAL PROTEINS**                                                                                                                                                                                                                                              
  11005                                TNFAIP3-interacting protein 2                                               ABIN2              Q99JG7                         6.03     49,094          78        8                             23                −1.792            0.00449
  11105                                Cell death regulator Aven                                                   AVEN               Q9D9K3                         4.92     37,195          59        5                             21                −1.887            0.03471
  12856                                Regulator of G-protein signaling 10                                         RGS10              Q9CQE5                         6.36     21,151          66        4                             44                1.805             8.22E-05
  **OTHER**                                                                                                                                                                                                                                                               
  12115                                Phosphoserine phosphatase                                                   PSPH               Q99LS3                         5.81     25,096          56        4                             36                1.434             0.01847
  11051                                Calcium/calmodulin-dependent 3′,5′-cyclic nucleotide phosphodiesterase 1A   PDE1A              Q61481                         5.67     64,529          82        7                             15                −1.514            0.00902
  11988                                Galanin-like peptide                                                        GALP               Q810H5                         6.41     12,773          61        3                             35                −5.496            0.03014
  12051                                Glyoxalase domain-containing protein 5                                      GLOD5              Q9D8I3                         5.12     16,595          59        4                             40                −1.827            0.03871

![**Adolescent hippocampal proteomics comparing adolescent vehicle-treated WT and *Nrg1* HET mice. (A)** Representative 2DE gel images showing positions of significantly altered protein spots \[the horizontal axis split by isoelectric point, vertical axis split by molecular weight; STX1A (spot 11755); TPH1 (spot 11967); β-SNAP (spot 11358); SPARC (spot 11646); GPC6 (spot 11294)\]; and **(B)** Exemplar normalized volumes of altered proteins i.e., STX1A, β-SNAP and GPC6. The inset for STX1A shows immunoblots against STX1A and loading control alpha-tubulin (TUBA), confirming greater expression of STX1A in *Nrg1* HET versus WT mice.](fncel-07-00015-g0001){#F1}

THC induced changes in 28 spots and 23 spots in WT and *Nrg1* HET mice respectively relative to vehicle-treated mice within the same genotype. From these comparisons, 4 and 10 proteins were identified as being significantly altered by THC exposure in adolescent WT and *Nrg1* HET mice and fold changes are listed in Table [2](#T2){ref-type="table"} (relative to WT mice treated with vehicle) and 3 (relative to *Nrg1* HET mice treated with vehicle) respectively. Figure [2A](#F2){ref-type="fig"} shows a representative 2D gel image of protein expression in the hippocampus of an adolescent WT mouse administered repeated THC injections. Normalized spot volumes are depicted for 3 representative proteins in Figure [2B](#F2){ref-type="fig"}, i.e., glutathione S-transferase Mu 2 (GSTM2), calretinin (CALB2) and ADP-ribosylation factor-like protein 1 (ARL1). *Nrg1* HET mice treated with THC displayed a distinct protein expression profile to WT mice exposed to the drug. Figure [3A](#F3){ref-type="fig"} shows a representative 2D gel image of protein expression in the hippocampus of an adolescent *Nrg1* HET mouse administered repeated THC. Normalized spot volumes of three representative proteins are depicted in Figure [3B](#F3){ref-type="fig"}, i.e., G-protein-signaling modulator 2 (GPSM2), apolipoprotein A1 (APOA1) and N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NAPEPLD).

###### 

**Adolescent hippocampal proteomics comparing adolescent WT mice treated with vehicle and THC**.

  **Spot number**                     **Protein name**                         **Abbreviation**   **UniProt accession number**   **PI**   **Mass (Da)**   **MWS**   **No. of peptides matched**   **% seq cover**   **Fold change**   ***T*-test (p)**
  ----------------------------------- ---------------------------------------- ------------------ ------------------------------ -------- --------------- --------- ----------------------------- ----------------- ----------------- ------------------
  **OXIDATION REGULATION PROTEINS**                                                                                                                                                                                                   
  11418                               Glutathione S-transferase Mu 2           GSTM2              P15626                         6.9      25,717          73        5                             20                −1.759            0.02679
  11769                               Heat shock 70 kDa protein 4              HSPA4              Q61316                         5.15     94,133          95        8                             14                2.137             0.04305
  **OTHER**                                                                                                                                                                                                                           
  11103                               Calretinin                               CALB2              Q08331                         4.94     31,373          66        4                             21                −1.748            0.03045
  11677                               ADP-ribosylation factor-like protein 1   ARL1               P61211                         5.63     20,412          57        3                             20                −2.869            0.04051

![**Adolescent hippocampal proteomics comparing adolescent WT mice treated with vehicle and THC. (A)** Representative 2DE gel images showing positions of significantly altered protein spots, the horizontal axis split by isoelectric point, vertical axis split by molecular weight; \[CALB2 (spot 11103); ARL1 (spot 11677); GSTM2 (spot 11418); HSPA4 (spot 11769)\]; and **(B)** Exemplar normalized volumes of altered proteins i.e., CALB2, ARL1, and GSTM2.](fncel-07-00015-g0002){#F2}

![**Adolescent hippocampal proteomics comparing adolescent *Nrg1* HET mice treated with vehicle and THC. (A)** Representative 2D E gel images showing positions of significantly altered protein spots (the horizontal axis split by isoelectric point, vertical axis split by molecular weight; \[GPSM2 (spot 11713); APOA1 (spot 11674); NAPEPLD (spot 11060); OTOR (spot 12395)\]; and **(B)** exemplar normalized volumes of altered proteins i.e., GPSM2, APOA1 and NAPEPLD.](fncel-07-00015-g0003){#F3}

Discussion {#s4}
==========

*Nrg1* HET mice, displayed altered expression of a number of proteins involved in the vesicular release of neurotransmitters including STX1A, syntaxin 7 (STX7) and β-SNAP; serotonergic neurotransmission including tryptophan 5-hydroxylase 1 (TPH1) and serotonin N-acetyltransferase (AA-NAT); growth factor expression and regulation including secreted protein acidic and rich in cysteine (SPARC) and GPC6, and; cell survival and regulators of inflammatory cytokines including cell death regulator Aven (AVEN), TNFAIP3-interacting protein 2 (ABIN2) and regulator of G-protein signaling 10 (RGS10). We replicated prior findings in rodents without genetic modification showing THC reduced the hippocampal expression of GSTM2 and affected the expression of heat shock proteins (here HSPA4). We also identified novel proteins changed in response to repeated THC exposure, that is, CALB2 and ARL1. Unlike WT mice, *Nrg1* HET mice administered THC displayed altered expression of proteins involved in NMDA receptor trafficking to the synaptic membrane including GPSM2; lipid raft stabilization of receptors at the synaptic membrane including flotillin-1 (FLOT1); homeostatic responses to dampen excessive glutamatergic transmission, including NAPEPLD, and excitotoxicity and apoptosis including programmed cell death protein 2 (PCD2). Figure [4](#F4){ref-type="fig"} is a schematic proposing an overview of the proteins found to have altered expression in the current study and their potential functional significance. Proteomics may produce false positives and fold changes \< 1.5 should be interpreted cautiously. Nevertheless, these results, while suggestive rather than conclusive, provide a platform for future work to confirm and more fully characterize the role of various novel proteins in the effects of *Nrg1* hypomorphism, THC and *Nrg1*-THC interactions.

![**Schematic representation of altered proteins. (A)** Proteins with different expression in *Nrg1* HET mice relative to WT controls; and **(B)** Proteins with different expression in THC administered *Nrg1* HET mice relative to vehicle treated controls.](fncel-07-00015-g0004){#F4}

Distinct protein expression in the hippocampus of adolescent *Nrg1* HET and WT mice
-----------------------------------------------------------------------------------

Disordered neurotransmission is involved in the pathophysiology of schizophrenia and *NRG1*, a schizophrenia susceptibility gene, regulates neurotransmitter receptor expression and synaptic plasticity (Mei and Xiong, [@B59]). Here we provide evidence that heterozygous deletion of *Nrg1* alters numerous proteins involved in the transport, fusion and recycling of synaptic vesicles, all processes critical to neurotransmitter release and synaptic function. The soluble N-ethylmaleimide-sensitive fusion attachment protein receptor (SNARE) complex regulates exocytotic release of neurotransmitters from presynaptic terminals and alterations in SNARE mRNA and protein is observed in post-mortem schizophrenia brain (Ramakrishnan et al., [@B72]). Here we show for the first time that *Nrg1* hypomorphism alters the expression of various SNARE proteins including STX1A, STX7, and β-SNAP.

STX1A was increased almost three-fold in *Nrg1* HET mice relative to WT controls and this change was confirmed by Western blot analysis. Located within the pre-synaptic membrane, STX1A combines with 25 kDa synaptosome-associated protein SNAP25 and vesicle-associated membrane protein 2 to form a complex that drives vesicle and presynaptic membrane fusion necessary for neurotransmitter exocytosis. Concordant with our findings in *Nrg1* HET mice, STX1A is upregulated in the hippocampus and cingulate cortex of schizophrenic patients (Gabriel et al., [@B29]; Honer et al., [@B39]; Sokolov et al., [@B81]; Clark et al., [@B22]). We also demonstrate here that STX7, a member of an endocytic SNARE complex, was upregulated in *Nrg1* HET mice compared to WT mice. STX7 mediates endocytic trafficking from early endosomes to late endosomes, and is necessary for fusion of late endosomes to lysosomes (Mullock et al., [@B61]; Nakamura et al., [@B63]). β-SNAP displayed an almost 9-fold reduction in expression in *Nrg1* HET mice compared to WT mice. β-SNAP belongs to a class of proteins known as SNAPs, which form complexes with SNARE proteins to assist with membrane fusion before being dissociated by the ATPase N-ethylmaleimide-sensitive factor. In contrast to other SNAPs, β-SNAP is localized to neural tissue, including hippocampal cells (Schiavo et al., [@B79]).

*Nrg1* HET mice also displayed altered expression of several proteins involved in protein transport between the endoplasmic reticulum (ER) and Golgi apparatus. These included β-SNAP, dynactin subunit 2 (DCTN2) and ADP-ribosyl cyclase 2 (BST-1). Transport of protein from the ER to the Golgi is important to protein sorting and the dispatch of protein to cellular locations. An increased expression of DCTN2 was also observed in *Nrg1* HET mice. DCTN2 is a functional subunit of dynactin, a component of the dynein-dynactin system. DCTN2 overexpression inhibits dynactin, and therefore dynein functions such as dynein-dependent maintenance of membrane organelle distribution (Burkhardt et al., [@B15]). DCTN2 is associated with syntaxin 18, an ER-localized SNARE involved in membrane trafficking between the ER and Golgi (Arasaki et al., [@B3]). BST-1, which was downregulated in *Nrg1* HET mice, is also implicated in ER to Golgi transport as it suppressed such trafficking in yeast cells (Sompol et al., [@B82]).

Previous studies suggest that *Nrg1* hypomorphism affects serotonergic neurotransmission, by altering the expression of 5-HT~2A~ receptors and the serotonin transporter in various brain regions of both adolescent and adult mice (Dean et al., [@B24]; Long et al., [@B54]). The observation that *Nrg1* HET mice had reduced expression of TPH1 and increased level of AA-NAT is consistent with this notion. TPH1 is one of two isoforms of the enzyme involved in the rate-limiting synthesis of serotonin. Polymorphism in *TPH1* is associated with increased risk for various psychiatric disorders including schizophrenia and bipolar disorder (Saetre et al., [@B77]; Seifuddin et al., [@B80]) and varies with neurodevelopment with peaks at PND 21 before decreasing in adulthood (Nakamura et al., [@B62]). Given the autocrine role of serotonin in guiding the development of serotonergic neurons (Gaspar et al., [@B31]), reduced TPH1 expression in adolescent *Nrg1* HET mice may reflect aberrant development of serotonergic brain circuitry in these mice. AA-NAT, which converts serotonin to N-acetylserotonin, was also upregulated in the hippocampus of *Nrg1* HET mice. This role of this enzyme is well characterized in the pineal gland due to its involvement in melatonin synthesis and sleep-wake cycles (Zheng and Cole, [@B100]). However, the function of AA-NAT in other brain regions including the hippocampus is poorly understood. AA-NAT is expressed in a non-diurnal dependent manner in the hippocampus (Uz et al., [@B91]) and promotes hippocampal neuroprogenitor cell proliferation in mice (Sompol et al., [@B82]).

Given that *Nrg1* is a neurotrophic factor it is not entirely surprising that *Nrg1* HET mice display altered expression of the growth factor fibroblast growth factor 14 (FGF14) and regulators of growth factor protein expression, including SPARC and GPC6. FGF14 knockout mice, like *Nrg1* HET mice, display locomotor hyperactivity, spatial learning deficits and impaired hippocampal long-term potentiation associated with lowered presynaptic vesicle docking (Wozniak et al., [@B98]; Xiao et al., [@B99]). The latter effect is relevant given the altered proteins involved in vesicle docking we observed here in *Nrg1* HET mice. The reduced level of FGF14 might be related to the increased expression of GPC6 and SPARC. Glypicans are heparan sulphate proteoglycans that act as co-receptors for growth factors and modulate fibroblast growth factor signaling (Paine-Saunders et al., [@B68]; Galli et al., [@B30]). GPC6 has recently been identified as a gene that confers susceptibility to formal thought disorder in schizophrenia and as a factor released from astrocytes that supports the formation of glutamatergic synapses via GluA1 AMPA receptors (Allen et al., [@B2]; Wang et al., [@B95]). Similar to GPC6, SPARC is released from astrocytes and modulates the formation of excitatory synapses and FGF expression (Kucukdereli et al., [@B48]; Bradshaw, [@B14]). Taken together these findings suggest a novel link between *Nrg1* and other interrelated growth factor-related proteins FG14, GPC6, and SPARC, worthy of further examination in future studies.

The hippocampus of adolescent *Nrg1* HET mice displayed altered expression of various proteins that influence cell survival and neuroinflammation including AVEN, ABIN2, and RGS10. *Nrg1* exerts neuroprotective effects via inhibiting apoptosis triggered by various challenges (Chen et al., [@B18]; Li et al., [@B52]; Woo et al., [@B97]). AVEN inhibits apoptosis (Chau et al., [@B17]; Figueroa et al., [@B27]; Kutuk et al., [@B49]), therefore the reduction of AVEN in the hippocampus of *Nrg1* HET mice might confer greater vulnerability to apoptosis in these mice. Adolescent *Nrg1* HET mice displayed a trend toward increased expression of the pro-apoptotic and inflammatory cytokine TNF-α in the hippocampus and schizophrenia patients with a missense mutation in the transmembrane domain of *NRG1* show heightened expression of TNF-α from B cells (Marballi et al., [@B56]; Desbonnet et al., [@B25]). This is interesting as ABIN-2 and RGS10, two proteins altered in *Nrg1* HET mice, modulate the action of the TNF-α. ABIN-2 prevents TNF-α mediated pro-apoptotic effects and its decreased expression in *Nrg1* HET mice might reflect again a greater propensity to hippocampal apoptosis (Verstrepen et al., [@B92]). Perhaps as a compensatory mechanism *Nrg1* HET mice showed increased expression of RGS10, a protein which renders cells resistant to TNF-α induced apoptosis (Lee et al., [@B50]). Future studies are required to confirm whether altered apoptosis and neuroinflammation exists in *Nrg1* HET mice.

Differential effects of THC on the proteome of *Nrg1* HET mice vs. WT mice
--------------------------------------------------------------------------

Our prior research shows that *Nrg1* heterozygotes display an altered neurobehavioral response to cannabinoids (Boucher et al., [@B10],[@B11], [@B12]; Arnold et al., [@B4]; Long et al., [@B54]). *Nrg1* mutant mice were more sensitive to the behavioral actions of acute THC compared to WT littermates in a sex-specific manner, with males being selectively affected but not females (Boucher et al., [@B10]; Long et al., [@B53]). In a repeated dosing study, tolerance to cannabinoid-induced hypothermia and locomotor suppression developed more rapidly in *Nrg1* HET than WT mice (Boucher et al., [@B12]). Conversely, only WT mice developed tolerance to cannabinoid-induced anxiety and *Nrg1* HET mice maintained a persistent anxiogenic response to repeated cannabinoid exposure. Acute and repeated cannabinoid exposure selectively activated expression of Fos transcription factors in the lateral septum of *Nrg1* HET mice but not WT mice (Boucher et al., [@B11], [@B12]). We also examined whether *Nrg1* hypomorphism confers vulnerability to the neurobehavioral actions of acute or repeated THC exposure in adolescence (Long et al., [@B54]). THC exposure exacerbated the hyperlocomotor phenotype of *Nrg1* HET mice expressed after withdrawal of the drug. Further, repeated THC administration also promoted differential effects on CB~1~ receptor, 5-HT~2A~ and NMDA receptor binding. Notably adolescent THC exposure selectively increased NMDA receptor expression in the hippocampus of *Nrg1* HET but not WT mice. Given these findings it is perhaps not surprising that the impact of repeated THC treatment as measured by proteomics was quite distinct in *Nrg1* HET mice vs. WT mice, with no overlap in differentially expressed proteins Table [3](#T3){ref-type="table"}.

###### 

**Adolescent hippocampal proteomics comparing adolescent *Nrg1* HET mice treated with vehicle and THC**.

  **Spot number**                                   **Protein name**                                              **Abbreviation**   **UniProt accession number**   **PI**   **Mass (Da)**   **MWS**   **No. of peptides matched**   **% seq cover**   **Fold change**   ***T*-test (p)**
  ------------------------------------------------- ------------------------------------------------------------- ------------------ ------------------------------ -------- --------------- --------- ----------------------------- ----------------- ----------------- ------------------
  **NMDA RECEPTOR PHYSIOLOGY**                                                                                                                                                                                                                                           
  11396                                             Flotillin-1                                                   FLOT1              O08917                         6.71     47,513          82        6                             16                1.54              0.001985
  11674                                             Apolipoprotein A-I                                            APOA1              Q00623                         5.64     30,616          73        5                             19                2.069             0.003538
  11713                                             G-protein-signaling modulator 2                               GPSM2              Q8VDU0                         6.49     75,591          77        7                             15                −2.648            0.04831
  **CELL SURVIVAL/CYTOTOXICITY RELATED PROTEINS**                                                                                                                                                                                                                        
  12338                                             Programmed cell death protein 2 (fragment)                    PDCD2              Q6RI66                         5.24     19,190          66        9                             19                1.169             0.0391
  11060                                             N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D   NAPEPLD            Q8BH82                         5.63     45,816          78        6                             21                2.334             0.02612
  11078                                             Interleukin-2                                                 IL-2               P04351                         4.66     19,400          58        3                             34                −1.48             0.03401
  **OTHER**                                                                                                                                                                                                                                                              
  11273                                             Translocon-associated protein subunit alpha                   SSR1               Q9CY50                         4.36     32,065          56        4                             20                −3.383            0.02365
  11684                                             Carbonic anhydrase 3                                          CA3                P16015                         6.89     29,366          97                                      42                −1.293            0.03876
  11348                                             Vacuolar protein-sorting-associated protein 25                VPS25              Q9CQ80                         5.97     20,748          62        4                             33                −3.211            0.04376
  12395                                             Otoraplin                                                     OTOR               Q9JIE3                         4.77     14,328          61        3                             21                3.159             0.0296

Nevertheless, our findings show some degree of overlap with previous examinations of THC effects on the rodent brain proteome (Quinn et al., [@B69]; Colombo et al., [@B23]; Rubino et al., [@B75]; Filipeanu et al., [@B28]; Wang et al., [@B94]). THC treatment in adolescent rats modulated proteins regulating oxidative stress such as glutathione S-transferase and heat shock proteins (Quinn et al., [@B69]). Our results replicate the finding that repeated THC exposure decreased the expression of GSTM2 in the hippocampus (Quinn et al., [@B69]). GSTM2 catalysis the conjugation of reduced glutathione to electrophilic compounds thereby reducing the deleterious effects of reactive oxygen species (ROS) on cellular lipid, protein and DNA. By reducing levels of GSTM2, THC may render the hippocampus more vulnerable to oxidative stress and this may be linked to the long-term memory impairing effects of cannabinoids (Quinn et al., [@B69]; Boucher et al., [@B13]). Phencyclidine, another drug of abuse that promotes schizophrenia-relevant behaviors and cognitive dysfunction, also reduced glutathione levels and antioxidant defense enzymes in the rodent brain (Radonjic et al., [@B70]; Stojković et al., [@B87]). Interestingly, copy number variants in genes encoding glutathione S-transferase may be involved in susceptibility to schizophrenia (Rodriguez-Santiago et al., [@B73]). Here we also showed repeated adolescent THC exposure upregulated the expression of heat shock protein 70 kDa in the hippocampus. Previous studies illustrated effects of rodent THC exposure on heat shock protein 70 kDa, heat shock cognate 71 kDa protein and heat shock 60 kDa protein (Bindukumar et al., [@B8]; Quinn et al., [@B69]; Colombo et al., [@B23]; Rubino et al., [@B75]; Filipeanu et al., [@B28]). Heat shock proteins regulate cellular stress responses and provide protection against oxidative stress (Quinn et al., [@B69]; Stetler et al., [@B86]) so their increased expression may signify greater oxidative stress in the hippocampus. Heat shock protein 70 kDa may also serve an autophagic function facilitating the clearance of toxic proteins and assisting in neuronal survival (Stetler et al., [@B86]).

Adolescent THC exposure decreased hippocampal levels of the calcium-binding protein CALB2. CB~1~ receptors are expressed on calretinin-positive GABA interneurons in the hippocampus (Marsicano and Lutz, [@B57]; Morozov et al., [@B60]). THC exposure in C57/BL6 mice increased expression of this protein in the cerebellum (Colombo et al., [@B23]). Colombo et al. ([@B23]) analyzed CALB2 expression in the membrane whereas we assessed the cytosolic fraction, therefore it remains possible our finding may reflect translocation of the protein from the cytosol to the membrane. We isolated a novel protein, (ARL1), which was downregulated in response to THC exposure. Alcohol and methamphetamine administration similarly alter expression of this protein (Iwazaki et al., [@B43]; Kobeissy et al., [@B47]; Kashem et al., [@B46]). ARL1 is a Ras GTPase involved in retrograde trafficking of endosomes between the Golgi apparatus and the membrane in mammalian cells (Nishimoto-Morita et al., [@B65]). A THC-induced reduction in ARL1 may then disrupt the distribution of intracellular protein transport in the hippocampus.

Proteins selectively altered in *Nrg1* HET mice treated with THC include those that affect synapse formation and the dynamics of dendritic spines. *Nrg1* is a neurotrophic factor involved in spinogenesis through its modulation of NMDA receptor function (Li et al., [@B51]; Chen et al., [@B19]; Barros et al., [@B6]; Bennett, [@B7]; Nason et al., [@B64]). Adolescent THC exposure reduced the density of dendritic spines in the hippocampus via modulation of a number of proteins important to spine dynamics such as PSD-95 and NMDA receptors (Rubino et al., [@B76]). *Nrg1* hypomorphism might abnormally increase dendritic spine density in the hippocampus in response to THC as adolescent *Nrg1* HET mice treated with THC displayed increased NMDA receptor binding in the hippocampus (Long et al., [@B54]). Our proteomic findings indicate altered expression in a number of proteins involved in intracellular trafficking and stabilization of NMDA receptors at the synapse. These include FLOT1, APOA1, and GPSM2.

GPSM2 traffics intracellular NMDA receptors to the synaptic membrane and facilitates spinogenesis by forming a macromolecular complex with NMDA receptors and synapse associated protein 102 (Sans et al., [@B78]). The reduced level of GPSM2 we observed in THC-treated *Nrg1* HET mice may reflect GPSM2 being incorporated into the macromolecular complex, lowering the observed expression of free, unconjugated GPSM2. Further, *Nrg1* HET mice treated with THC showed a selective increase in FLOT1 expression in the hippocampus, a protein that helps stabilize lipid rafts in the membrane. FLO T1 mediates neurite branching and dendritic spine dynamics in the hippocampus (Swanwick et al., [@B88]; Raemaekers et al., [@B71]). It also regulates the formation of glutamatergic synapses and interacts with NMDA receptors, possibly to enhance NMDA receptor clustering or trafficking to the membrane (Allen et al., [@B1]; Swanwick et al., [@B89], [@B88]). Lipid rafts are constituted by cholesterol and sphingolipids (Mauch et al., [@B58]; Hering et al., [@B36]). APOA1, a protein that stimulates cholesterol release from glia, was upregulated in THC exposed *Nrg1* HET mice (Hirsch-Reinshagen et al., [@B38]; Karten et al., [@B45]). Therefore, APOA1, by increasing the availability of cholesterol for incorporation into lipid rafts, may have in turn assisted in the molecular events required to stabilize NMDA receptors at the synaptic membrane. Interestingly, APOA1 is altered in schizophrenia brain (Huang et al., [@B42]).

The increased excitatory transmission mediated by increased NMDA receptors in THC-treated *Nrg1* HET mice might also increase the expression of the apoptotic marker PCD2 and anandamide synthesizing enzyme NAPEPLD (Howlett et al., [@B41]), proteins reflecting heightened excitotoxicity/apoptosis and a homeostatic attempt to dampen increased NMDA receptor activation respectively. These results are consistent with *Nrg1*-cannabinoid interactions dysregulating the septohippocampal system. Increased excitation in the hippocampus of THC-treated *Nrg1* HET mice might then influence downstream activity of the lateral septum, a region we have repeatedly shown to be selectively activated in *Nrg1* HET mice in response to THC (Boucher et al., [@B11], [@B12]).

Conclusions {#s5}
===========

Using a proteomic approach we have uncovered numerous novel proteins that may be subject to regulation by disturbed *Nrg1* signaling. Our findings also illuminate a potential constellation of molecular changes that may subserve the behavioral abnormalities that are observed in the *Nrg1* transmembrane domain heterozygous mouse as well as their idiosyncratic response to repeated cannabinoid treatment. This may have implications for our overall understanding of genetic vulnerability to schizophrenia and to the exacerbation of psychosis sometimes caused by cannabis.
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